Abstract
One glucagon-like peptide-1 (GLP-1) agonist, liraglutide (Saxenda), is approved for treating obesity. Now, another GLP-1 agonist, semaglutide (marketed
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have